Institut d'Investigacions Biomèdiques August Pi i Sunyer   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Barcelona Spain (1993)

Organization Overview

First Clinical Trial
2014
NCT03557541
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer | Institut d'Investigacions Biomèdiques August Pi i Sunyer | Sara V. Latorre

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

Communicable Diseases (Phase 2)

Fibrosis (Phase 3)

HIV Infections (Phase 2)

Infections (Phase 2)

Leukemia (Phase 1)

Liver Cirrhosis (Phase 3)

Lymphoma (Phase 1)

Multiple Myeloma (Phase 2)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 27